Lack of association between MDR1 C3435T polymorphism and chemotherapy response in advanced breast cancer patients: Evidence from current studies

Molecular Biology Reports

Volumn 39, Issue 5, 2012, Pages 5161-5168

  Chen, Guodi ^a   Quan, Sheng ^b   Hu, Qiongge ^a   Wang, Liancong ^a   Xia, Xiaoping ^c   Wu, Jing ^d  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY CITY COLLEGE   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Breast cancer; Chemotherapy; MDR1; Meta analysis; Polymorphism

Indexed keywords

ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; TAXANE DERIVATIVE; ABCB1 PROTEIN, HUMAN; GLYCOPROTEIN P;

ADVANCED CANCER; ARTICLE; ASIAN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CAUCASIAN; DISEASE ASSOCIATION; DNA POLYMORPHISM; ETHNICITY; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MULTIDRUG RESISTANCE GENE 1; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TUMOR GENE; BREAST TUMOR; CANCER STAGING; FEMALE; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION; GENETICS; PATHOLOGY; PUBLISHING; RISK; SINGLE NUCLEOTIDE POLYMORPHISM;

BREAST NEOPLASMS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASM STAGING; ODDS RATIO; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PUBLICATION BIAS;

EID: 84863752522     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-011-1312-2     Document Type: Article

References (41)

1. Ferlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917
2. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71-96
3. Fan L, Zheng Y, Yu KD et al (2009) Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China. Breast Cancer Res Treat 117:409-416
4. Gor PP, Su HI, Gray RJ et al (2010) Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Res 12:R26
5. Breier A, Barancik M, Sulova Z et al (2005) P-glycoprotein-implications of metabolism of neoplastic cells and cancer therapy. Curr Cancer Drug Targets 5:457-468
6. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48-58
7. Soto-Vega E, Arroyo C, Richaud-Patin Y et al (2009) P-glycoprotein activity in renal clear cell carcinoma. Urol Oncol 27:363-366
8. Vlachogeorgos GS, Manali ED, Blana E et al (2008) Placental isoform glutathione S-transferase and P-glycoprotein expression in advanced nonsmall cell lung cancer: association with response to treatment and survival. Cancer 114:519-526
9. Gouaze V, Yu JY, Bleicher RJ et al (2004) Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol Cancer Ther 3:633-639
10. Burger H, Foekens JA, Look MP et al (2003) RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res 9:827-836
11. Mutoh K, Tsukahara S, Mitsuhashi J et al (2006) Estrogenmediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells. Cancer Sci 97:1198-1204
12. Hoffmeyer S, Burk O, von Richter O et al (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478
13. Nauck M, Stein U, von Karger S et al (2000) Rapid detection of the C3435T polymorphism of multidrug resistance gene 1 using fluorogenic hybridization probes. Clin Chem 46:1995-1997
14. Tahara T, Arisawa T, Shibata T et al (2007) Multi-drug resistance 1 polymorphism is associated with reduced risk of gastric cancer in the Japanese population. J Gastroenterol Hepatol 22:1678-1682
15. Maffioli M, Camos M, Gaya A et al (2010) Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronicphase chronic myeloid leukemia. Leuk Res 35:1014-1019
16. Ni LN, Li JY, Miao KR et al (2011) Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol 28:265-269
17. Kafka A, Sauer G, Jaeger C et al (2003) Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol 22:1117-1121
18. Ashariati A (2008) Polymorphism C3435T of the MDR-1 gene predict response to preoperative chemotherapy in locally advanced breast cancer with Her2/neu expression. Acta Med Indones 40:187-191
19. Cizmarikova M, Wagnerova M, Schonova L et al (2010) MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J 10:62-69
20. Zhang BL, Sun T, Zhang BN et al (2011) Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer. Chin Med J (Engl) 124:199-204
21. Cochran W (1954) The combination of estimates from different experiments. Biometrics 10:101-129
22. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188
23. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539-1558
24. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748
25. Egger M, Davey Smith G, Schneider M et al (1997) Bias in metaanalysis detected by a simple, graphical test. BMJ 315:629-634
26. George J, Dharanipragada K, Krishnamachari S et al (2009) A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer. Clin Breast Cancer 9:161-165
27. George J, Dharanipragada K, Krishnamachari S et al (2009) Association of the ABCB1 gene polymorphisms 2677G[T/A and 3435C[T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol 20:272-277
28. Rodrigues FF, Santos RE, Melo MB et al (2008) Correlation of polymorphism C3435T of the MDR-1 gene and the response of primary chemotherapy in women with locally advanced breast cancer. Genet Mol Res 7:177-183
29. Zintzaras E, Ziogas DC, Kitsios GD et al (2009) MTHFR gene polymorphisms and response to chemotherapy in colorectal cancer: a meta-analysis. Pharmacogenomics 10:1285-1294
30. Verrelle P, Meissonnier F, Fonck Y et al (1991) Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 83:111-116
31. Leonessa F, Clarke R (2003) ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 10:43-73
32. Chevillard S, Lebeau J, Pouillart P et al (1997) Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy. Clin Cancer Res 3:2471-2478
33. Tanabe M, Ieiri I, Nagata N et al (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297:1137-1143
34. Levine MN, Whelan T (2006) Adjuvant chemotherapy for breast cancer-30 years later. N Engl J Med 355:1920-1922
35. Merk J, Rolff J, Dorn C et al (2011) Chemoresistance in nonsmall-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy? Eur J Cardiothorac Surg 40:e29-e33
36. Moureau-Zabotto L, Ricci S, Lefranc JP et al (2006) Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients. Br J Cancer 94:473-480
37. Schwab M, Eichelbaum M, Fromm MF (2003) Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 43:285-307
38. Illmer T, Schuler US, Thiede C et al (2002) MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 62:4955-4962
39. Sohn JW, Lee SY, Lee SJ et al (2006) MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn J Clin Oncol 36:137-141
40. Isla D, Sarries C, Rosell R et al (2004) Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15:1194-1203
41. Jiko M, Yano I, Sato E et al (2007) Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers. Int J Clin Oncol 12:284-290